Tekmira Pharmaceuticals Corporation  

(Public, TSE:TKM)   Watch this stock  
Find more results for TKM
15.30
-0.61 (-3.83%)
Delayed:   2:59PM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 15.08 - 16.22
52 week 8.00 - 34.66
Open 16.22
Vol / Avg. 51,685.00/66,505.00
Mkt cap 355.69M
P/E     -
Div/yield     -
EPS -1.98
Shares 22.31M
Beta 0.13
Inst. own     -
Nov 21, 2014
Tekmira Pharmaceuticals Corp Analyst and Investor Day
Nov 19, 2014
Tekmira Pharmaceuticals Corp at Stifel Healthcare Conference
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Call
Nov 6, 2014
Q3 2014 Tekmira Pharmaceuticals Corp Earnings Release
Oct 7, 2014
Tekmira Pharmaceuticals Corp at BIO Investor Forum
Oct 1, 2014
Tekmira Pharmaceuticals Corp at Leerink Rare Disease Roundtable
Sep 22, 2014
Tekmira Pharmaceuticals Corp at Maxim Group's Institutional NYC BioDefense Mini-Conference
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -

Address

Suite 100, 8900 Glenlyon Parkway
BURNABY, BC V5J 5J8
Canada
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

Description

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company�s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.

Officers and directors

Daniel L. Kisner M.D. Independent Chairman of the Board
Age: 67
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Ian MacLachlan Ph.D. Executive Vice President, Chief Technical Officer
Age: 50
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
R. Hector MacKay-Dunn QC Corporate Secretary
Peggy V. Phillips Director
Age: 60
Donald G. Jewell Independent Director
Age: 60